Protara Therapeutics (TARA) Assets (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Assets of $191.9 million for Q1 2026, up 13.86% year-over-year from $168.6 million in Q1 2025, and down 8.38% quarter-over-quarter from $209.5 million in Q4 2025.
Protara Therapeutics (TARA) Assets (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Assets for 14 consecutive years, with $191.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 13.86% year-over-year to $191.9 million; the TTM figure through Mar 2026 stood at $191.9 million (up 13.86% YoY), while the FY2025 annual figure was $209.5 million, up 15.44% from the prior year.
- Assets slipped to $191.9 million in Q1 2026 per TARA's latest filing, from $209.5 million in the prior quarter.
- Across five years, Assets topped out at $209.5 million in Q4 2025 and bottomed at $68.1 million in Q1 2024.
- Historically, Assets has averaged $133.2 million across 5 years, with a median of $144.6 million in 2025.
- Annual changes were most pronounced in 2023 — Assets slumped 40.46% — and 2025, when it surged 147.39%.
- Protara Therapeutics' Assets stood at $113.3 million in 2022, then slumped by 30.31% to $79.0 million in 2023, then soared by 129.82% to $181.5 million in 2024, then rose by 15.44% to $209.5 million in 2025, then declined by 8.38% to $191.9 million in 2026.
- Business Quant data shows TARA's Assets at $191.9 million in Q1 2026, $209.5 million in Q4 2025, and $144.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 176.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176.09 Mn |
| Mar 31, 2026 | 191.92 Mn |
| Dec 31, 2025 | 209.47 Mn |
| Sep 30, 2025 | 144.64 Mn |
| Jun 30, 2025 | 156.93 Mn |
| Mar 31, 2025 | 168.56 Mn |
| Dec 31, 2024 | 181.45 Mn |
| Sep 30, 2024 | 94.09 Mn |
| Jun 30, 2024 | 101.65 Mn |
| Mar 31, 2024 | 68.13 Mn |
| Dec 31, 2023 | 78.95 Mn |
| Sep 30, 2023 | 88.47 Mn |
| Jun 30, 2023 | 95.14 Mn |
| Mar 31, 2023 | 106.41 Mn |
| Dec 31, 2022 | 113.29 Mn |
| Sep 30, 2022 | 148.59 Mn |
| Jun 30, 2022 | 154.88 Mn |
| Mar 31, 2022 | 161.26 Mn |
| Dec 31, 2021 | 172.60 Mn |
| Sep 30, 2021 | 180.70 Mn |